title: Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries.
abstract: Influenza viruses elude immune responses and antiviral chemotherapeutics through genetic drift and reassortment. As a result, the development of new strategies that attack a highly conserved viral function to prevent and/or treat influenza infection is being pursued. Such novel broadly acting antiviral therapies would be less susceptible to virus escape and provide a long lasting solution to the evolving virus challenge. Here we report the in vitro and in vivo activity of a human monoclonal antibody (A06) against two isolates of the 2009 H1N1 pandemic influenza virus. This antibody, which was obtained from a combinatorial library derived from a survivor of highly pathogenic H5N1 infection, neutralizes H5N1, seasonal H1N1 and 2009 "Swine" H1N1 pandemic influenza in vitro with similar potency and is capable of preventing and treating 2009 H1N1 influenza infection in murine models of disease. These results demonstrate broad activity of the A06 antibody and its utility as an anti-influenza treatment option, even against newly evolved influenza strains to which there is limited immunity in the general population.
authors.affiliation: Sea Lane Biotechnologies, Menlo Park, California, United States of America.
authors.forename: Arun K
authors.initials: AK
authors.lastname: Kashyap
authors.forename: John
authors.initials: J
authors.lastname: Steel
authors.forename: Adam
authors.initials: A
authors.lastname: Rubrum
authors.forename: Angeles
authors.initials: A
authors.lastname: Estelles
authors.forename: Raffaella
authors.initials: R
authors.lastname: Briante
authors.forename: Natalia A
authors.initials: NA
authors.lastname: Ilyushina
authors.forename: Li
authors.initials: L
authors.lastname: Xu
authors.forename: Ryann E
authors.initials: RE
authors.lastname: Swale
authors.forename: Aleksandr M
authors.initials: AM
authors.lastname: Faynboym
authors.forename: Pamela K
authors.initials: PK
authors.lastname: Foreman
authors.forename: Michael
authors.initials: M
authors.lastname: Horowitz
authors.forename: Lawrence
authors.initials: L
authors.lastname: Horowitz
authors.forename: Richard
authors.initials: R
authors.lastname: Webby
authors.forename: Peter
authors.initials: P
authors.lastname: Palese
authors.forename: Richard A
authors.initials: RA
authors.lastname: Lerner
authors.forename: Ramesh R
authors.initials: RR
authors.lastname: Bhatt
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000914:Antibodies, Viral / Q000627:therapeutic use*; D003429:Cross Reactions / Q000276:immunology; D004195:Disease Models, Animal; D004196:Disease Outbreaks; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology; D007251:Influenza, Human / Q000188:drug therapy* / Q000517:prevention & control; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000517:prevention & control; D017741:Survivors
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral